FMP

FMP

Enter

ABEO - Abeona Therapeutics ...

Financial Summary of Abeona Therapeutics Inc.(ABEO), Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapi

photo-url-https://financialmodelingprep.com/image-stock/ABEO.png

Abeona Therapeutics Inc.

ABEO

NASDAQ

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

5.31 USD

-0.03 (-0.565%)

About

ceo

Dr. Vishwas Seshadri M.B.A., Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biophar...

CIK

0000318306

ISIN

US00289Y2063

CUSIP

00289Y107

Address

1330 Avenue of the Americas

Phone

646 813 4701

Country

US

Employee

84

IPO Date

Sep 19, 1980

Summary

CIK

0000318306

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

00289Y107

ISIN

US00289Y2063

Country

US

Price

5.31

Beta

1.58

Volume Avg.

778.78k

Market Cap

217.51M

Shares

-

52-Week

2.83-9.01

DCF

-0.67

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.69

P/B

-

Website

https://www.abeonatherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ABEO News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep